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Abstract
In healthy subjects, we recently demonstrated that during acute administration
of GLP-1, cardiac output increased significantly, whereas renal blood flow
remained constant. We therefore hypothesize that GLP-1 induces vasodilation
in other organs, for example, adipose tissue, skeletal muscle, and/or splanchnic
tissues. Nine healthy men were examined twice in random order during a 2-
hour infusion of either GLP-1 (1.5 pmol kg1 min1) or saline. Cardiac out-
put was continuously estimated noninvasively concomitantly with measure-
ment of intra-arterial blood pressure. Subcutaneous, abdominal adipose tissue
blood flow (ATBF) was measured by the 133Xenon clearance technique. Leg
and splanchnic blood flow were measured by Fick’s Principle, using indocya-
nine green as indicator. In the GLP-1 study, cardiac output increased signifi-
cantly together with a significant increase in arterial pulse pressure and heart
rate compared with the saline study. Subcutaneous, abdominal ATBF and leg
blood flow increased significantly during the GLP-1 infusion compared with
saline, whereas splanchnic blood flow response did not differ between the
studies. We conclude that in healthy subjects, GLP-1 increases cardiac output
acutely due to a GLP-1-induced vasodilation in adipose tissue and skeletal
muscle together with an increase in cardiac work.
Introduction
We recently reported substantial acute effects of physiolog-
ically increased plasma levels of GLP-1 on cardiovascular
hemodynamics in humans, using continuous (invasive and
noninvasive) measurements (Asmar et al. 2015, 2016a). In
healthy individuals (Asmar et al. 2015) and patients with
type 2 diabetes (Asmar et al. 2016a), we demonstrated a
GLP-1-induced increase in heart rate, possibly due to
direct effects of GLP-1 on the heart (Pyke et al. 2014).
Furthermore, GLP-1 increased cardiac output in healthy
subjects (~18%, 1.2  0.1 L/min) but not in patients
with type 2 diabetes. Despite a significant renal clearance
of GLP-1, exceeding glomerular filtration (~55%),
renal blood flow and glomerular filtration rate remained
unchanged. The increase in cardiac output was propor-
tionally greater than the increase in mean arterial pres-
sure (~2%, 2.9  1.4 mmHg), suggesting a vasodilation
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in one or more vascular beds except for the renal
vascular bed.
Recently (Koska et al. 2015), it has been demonstrated
that GLP-1 receptors are functionally expressed in the
endothelium. GLP-1 receptor engagement improves
endothelial function in patients with type 2 diabetes. The
improved endothelial function is probably via stimulation
of endothelial AMP-activated protein kinase pathway
activity. This was demonstrated in isolated human adipose
tissue arterioles, resulting in a greater eNOS activity,
inducing vasodilation. However, the GLP-1-mediated
vasodilation may also occur by mechanisms independent
of the epithelium. Using a validated monoclonal antibody
for immunohistochemistry, Pyke et al. (2014) detected vas-
cular GLP-1 receptors exclusively in the smooth muscle
cells in arteries and arterioles. Engagement of the GLP-1
receptor in vascular smooth muscle cells leads to cAMP
formation and thereby activation of downstream paths
involving protein kinase A (PKA) and exchange protein
directly activated by cAMP (EPAC) (Drucker 2006). Both
PKA and EPAC induce intracellular Ca2+ accumulation,
initiating vascular relaxation via not fully clarified signaling
pathways (Gloerich and Bos 2010; Leech et al. 2010).
Using the flow-mediated dilation technique, Basu et al.
(2007) demonstrated, in healthy subjects, that acute infu-
sion of GLP-1 increases forearm blood flow in response
to acetylcholine, whereas Nystrom et al. (2004) demon-
strated that acute administration of GLP-1 increased fore-
arm blood flow in type 2 diabetes patients with stable
coronary artery disease, but not in healthy subjects. Using
real-time, contrast-enhanced ultrasound technique, Sjo-
berg et al. (2014) demonstrated microvascular recruit-
ment in the vastus lateralis muscle in healthy subjects
during an acute administration of GLP-1. Aside from this,
it is not fully clarified whether GLP-1, in vivo, modulates
vascular tonus in other beds, for example, adipose tissue
and/or splanchnic tissues.
Therefore, we designed the present randomized, pla-
cebo-controlled, and single-blinded experiment to eluci-
date whether acute administration of GLP-1, under fixed
sodium intake, induces vasodilation in adipose tissue, ske-
letal muscle, and/or splanchnic tissues in healthy subjects.
Materials and Methods
Subjects
Baseline characteristics are shown in Table 1. Nine lean
young male subjects of Caucasian origin participated in
the study, which involved two experiments performed in
random order separated by about 4 weeks. All subjects
were healthy and none took medication at the time of the
study. Body composition was determined by dual energy
X-ray absorptiometry (DEXA) scanning (Lunar iDXA; GE
Healthcare, Brøndby, Denmark) (Table 1). Consent to
participate was obtained after the subjects had read a
description of the experimental protocol, which was
approved by the Scientific Ethics Committee of the capital
region of Copenhagen (H-1-2014-089).
One subject developed syncope during the catheteriza-
tion procedures. Thus, only 133Xe washout data from this
subject were included in further analyses.
Protocol
For 4 days before each experiment all subjects consumed
a controlled mixed diet (2822 kcal per day, 16% protein,
55% carbohydrate, 29% fat). The food was handed out
frozen, and the basal sodium chloride content of the diet,
measured at Eurofins Stein’s Laboratory in Denmark, was
55-75 mmol per day. Sodium chloride was added to the
diet in order to standardize daily intake at 2 mmol
sodium chloride per kg body weight per day (Asmar et al.
2015, 2016a). 24-h urine was collected on the last day
and electrolyte, albumin, and glucose concentrations were
determined. Water intake was ad libitum, and strenuous
excess physical activity was not allowed. Subjects fasted
for 12 h before the beginning of the experiment. The
experimental timeline is shown in Figure 1. After empty-
ing the bladder, confirmed by ultrasound, subjects
remained supine throughout the experiments. During the
experiments, bladder emptying was allowed with subjects
remaining in the supine position.
Table 1. Baseline characteristics.
Variable Value
Age (years) 23  2
Height (cm) 183  3
Weight (kg) 78.0  4.3
Lean body mass (kg) 60.0  6.1
Whole body fat mass (kg) 14.8  5.2
Right leg lean mass (kg) 10.6  0.5
Right leg fat mass (kg) 2.6  0.3
Systolic blood pressure (mmHg) 126  9
Diastolic blood pressure (mmHg) 71  10
Heart rate (bpm) 56  9
Fasting glucose concentration (mmol/L) 5.4  0.3
Fasting insulin concentration (pmol/L) 17.8  15.1
Urinary albumin excretion (mg/24-h) 2.2  1.3
Urinary glucose excretion (mmol/24-h) 0.4  0.1
Body composition was determined by dual energy X-ray
absorptiometry (DEXA) scanning. Data are presented as
mean  SD.
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Catheterization
A forearm vein was catheterized with an 18 gauge catheter
(BD Venflon: length 45 mm, Becton Dickinson, Helsing-
borg, Sweden) for infusions. The right femoral vein was
catheterized using the Seldinger technique and a 7 F
introducer (Radifocus: length 110 mm, Terumo Corpo-
ration, Leuven, Belgium). A 6 F catheter (Check-Flo Per-
former: length 750 mm, Cook Medical, Bloomington,
IN) was advanced into a right-sided hepatic vein under
fluoroscopic control. The right femoral artery was
catheterized, using the Seldinger technique and a 3 F
catheter (Femoral Artery Catheter Set: length 80 mm,
Cook Medical, Bloomington, IN) for continuous infusion
of indocyanine green (ICG). In the nondominant arm,
the radial artery was catheterized with a 20 gauge catheter
(BD Arterial Cannula: length 45 mm, Becton Dickinson
Medical, Franklin Lakes, NJ) for blood sampling and for
continuous monitoring of arterial blood pressure. Blood
was collected simultaneously from the radial artery and
the femoral and hepatic vein throughout the experiments
as described below.
Blood flow measurements
Subcutaneous, abdominal ATBF was calculated from the
washout rate constant of 133Xenon. This technique has
previously been validated in our laboratory (Simonsen
et al. 2003). About 1.0 MBq gaseous 133Xenon mixed in
about 0.1 ml atmospheric air was injected into the para-
umbilical area of the subcutaneous adipose tissue. The
washout rate of 133Xenon was measured continuously by
a scintillation counter system (Oakfield Instruments,
Oxford, UK) strapped to the skin surface above the
133Xenon depot. Measurements obtained during periods
of 20 min throughout infusions were used for analyses.
Leg and splanchnic blood flow were measured via Fick’s
Principle, using ICG as indicator as previously described
(Enevoldsen et al. 2004; Hovind et al. 2010). An intra-
venous bolus injection of ICG (1 mg) in 10 mL of 0.9%
NaCl was administered followed by a continuous intra-
arterial infusion (167 lg min1) in 0.9% NaCl
(70 mL h1). Steady state arterial concentrations of ICG
were obtained after ~60 min. After at least 60 min of
infusion of ICG and after a stable monoexponential wash-
out of 133Xenon was registered, two baseline blood sample
pairs were drawn followed by start of a 2-h infusion of
either GLP-1 (1.5 pmol kg1 min1) or saline (0.9%
NaCl). The solutions were prepared freshly. The subjects
were blinded with respect to the contents.
Central hemodynamics
Blood pressure and heart rate were monitored invasively
(ADInstruments, Oxford, UK) throughout the experi-
ments. Estimated cardiac output was recorded continu-
ously and noninvasively using Finapres (Finapres Medical
Systems BV, Amsterdam, The Netherlands) (Imholz et al.
1998). The estimation of cardiac output via pulse contour
analysis is an indirect method based on the development
of the pulsatile unloading of the finger arterial walls using
an inflatable finger cuff with built-in photo-electric
plethysmograph (Langewouters et al. 1984, 1985). To
achieve highest accuracy and precision regarding absolute
stroke volume levels and cardiac output levels, a calibra-
tion of the Finapres against a direct method such as the
Fick’s Principle (e.g., indicator-dilution) is required. Such
calibration is, however, not necessary to observe relative
changes in cardiac output due to the GLP-1 infusion
(Stok et al. 1993; Bogert and van Lieshout 2005). Mea-
surements obtained during periods of ~5 min before and
after blood sampling were used for analyses.
Figure 1. The experimental timeline.
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Blood and urine analyses
Samples of blood were drawn simultaneously from the
radial artery and the right-sided femoral and hepatic vein
every 30 min from time 30 min until termination of
the experiments (Fig. 1). All arterial as well as venous
blood samples were analyzed for GLP-1 and ICG. Glucose
and insulin were analyzed only in arterial blood samples.
The amount of collected blood was substituted with a
similar amount of isotonic saline during the experiments.
Plasma samples were assayed for total GLP-1 immunore-
activity and for intact GLP-1, as previously described (Ors-
kov et al. 1994; Wewer Albrechtsen et al. 2015).
Concentrations of the primary metabolite GLP-1 9-36amide
were calculated by subtraction of concentrations of intact
GLP-1 from total concentrations (Meier et al. 2004).
Plasma insulin levels were measured using a commer-
cial enzyme immunoassay kit (Insulin Human ELISA
EIA-2935, AH Diagnostics, Aarhus, Denmark).
Blood glucose concentrations and hematocrit were
measured using an automated benchtop blood analyzer
system (ABL 700 series, Radiometer Medical Aps, Brøn-
shøj, Denmark).
Plasma ICG concentrations were determined by spec-
trophotometry at 805 and 904 nm in duplicates as previ-
ously described (Enevoldsen et al. 2005).
Urinary electrolyte concentrations were measured by
atomic absorption (Atomic absorption spectrophotometer
model 2380, PerkinElmer, Norwalk, Connecticut). Uri-
nary pH was measured using a XC161 Combination pH
electrode (Radiometer Medical Aps, Brønshøj, Denmark).
Urinary albumin and glucose concentrations were mea-
sured using an enzymatic method (Cobas Integra 400,
Roche Diagnostics, Indianapolis, IN).
Materials
Synthetic human GLP-1 7–36amide was obtained from
Clinalfa, Bachem (Bubendorf, Switzerland), ICG from
Pulsion Medical Systems (Feldkirchen, Germany), and
133Xenon from DRAXIMAGE (Quebec, Canada).
Calculations
The subcutaneous, abdominal ATBF was calculated from
the mean 133Xenon washout rate constant determined in
20-min periods. Thus, ATBF was calculated according to
the equation ATBF = k 9 k 9 100. A tissue/blood par-
tition coefficient (k) for Xenon of 10 mL g1 was used
(Bulow et al. 1987b).
Leg plasma flow was calculated as: ICG infusion-rate/
(ICGfemoral venous – ICGarterial) at steady state, and leg
blood flow was subsequently calculated from simultane-
ous measurements of hematocrit.
Splanchnic plasma flow was calculated as: ICG infu-
sion-rate/(ICGarterial – ICGhepatic venous) at steady state,
and splanchnic blood flow was calculated on the basis of
simultaneous measurements of hematocrit.
The extraction ratio of GLP-1 in the lower extremity
and splanchnic region was calculated as: (GLP-1arterial-
GLP-1venous)/GLP-1arterial.
Statistical analysis
The primary end-point in this study was the cardiac out-
put. When using a 2-tailed a = 0.05 and requiring an
80% power threshold, the sample size n < 6 was calcu-
lated to detect an appreciable effect of GLP-1 on cardiac
output. This calculation was based on our previous study
(Asmar et al. 2015), in which the effect magnitude of a
3-h intravenous GLP-1 infusion on cardiac output was
1.2 L min1 with an SD of 0.2 L min1.
Data were analyzed, using SigmaPlot 12 (Systat Software,
Inc., Chicago, IL) and GraphPad Prism 5 (GraphPad Soft-
ware, Inc., La Jolla, CA). Area under the curve (AUC) was
calculated, using the trapezoidal rule, and the t-test (2-tailed)
for paired data was used for comparing DAUC during the
GLP-1 infusion and DAUC during the saline infusion.
Values of P < 0.05 were considered statistically significant.
Results
Standardized sodium chloride intake
On the last day of the 4-day period with standardized
sodium chloride intake prior to the GLP-1 or saline
study, 24-h renal sodium excretions (data not shown)
were equal between subjects. Using samples from urine
collected throughout the GLP-1 and saline studies
(328  5 min and 333  9 min), mean urinary sodium,
potassium and hydrogen excretions were not statistically
different on the 2 days (data not shown).
Capillary GLP-1 degradation
Lower extremity and splanchnic arteriovenous plasma
levels of total GLP-1, intact GLP-1, and GLP-1 9-36amide
during the GLP-1 and saline infusions are shown in
Figure 2.
During the GLP-1 infusion, arterial plasma concentra-
tions of total GLP-1 increased significantly to
96  7 pmol/L (Fig. 2A) and femoral as well as hepatic
venous plasma concentrations increased significantly to
77  6 pmol/L (Fig. 2A) and 91  6 pmol/L (Fig. 2D),
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respectively. Analysis of the separate contributions of
intact GLP-1 7–36amide demonstrated a significant arteri-
ovenous concentration difference (femoral, ~30%, Fig. 2B
and hepatic, ~50%, Fig. 2E). The calculated GLP-1
9-36amide metabolite showed a smaller arteriovenous
concentration difference (femoral, ~25%, P = 0.090,
Fig. 2C), whereas no hepatic arteriovenous GLP-1
9–36amide concentration difference could be demon-
strated (Fig. 2F). During the saline infusion, arterial and
venous plasma concentrations of total GLP-1 remained
constant throughout the experiments, and a significant
arteriovenous concentration difference of GLP-1 could
not be demonstrated (Fig. 2A–F).
Effects of GLP-1 on arterial blood glucose
and plasma insulin
Arterial plasma insulin concentrations and arterial blood
glucose concentrations during the GLP-1 and saline infu-
sions are shown in Figure 3.
During the GLP-1 infusion, arterial plasma insulin con-
centrations tended to increase transiently from 16.6 pmol/L
to 21.0 pmol/L, whereas an increase was not seen during
the saline infusion (Fig. 3A and B). During the GLP-1 infu-
sion, arterial blood glucose concentrations were transiently
reduced (P = 0.001) (Fig. 3C and D) with a nadir of
4.36  0.12 mmol/L at 60 minutes, and with a range of
Figure 2. Arterial (radial) and venous (femoral and hepatic) plasma concentrations of total GLP-1 (A and D), intact GLP-1 (B and E), and GLP-1
9-36amide (C and F) during the GLP-1 or saline infusion. Data are presented as means  SE. *indicates statistically significant extraction of
GLP-1 during the GLP-infusion compared with saline.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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3.90–5.73 mmol/L within the first 60 min (Fig. 3C). None
of the subjects developed symptoms of hypoglycemia. After
a transient ~2-fold reduction in splanchnic glucose output
concomitant with the increase in insulin concentration
30 min after the commencement of the GLP-1 infusion,
the splanchnic glucose output returned to baseline level,
~1 mmol min1, indicating that the hypoglycemia did not
elicit significant metabolic counter regulation. During the
saline infusion, blood glucose concentrations remained
unchanged, and the splanchnic glucose output remained
constant ~1 mmol min1.
Effects of GLP-1 on central hemodynamics
Cardiac output, blood pressure and heart rate during
the GLP-1 and saline infusions are shown in Figure 4
and 5.
In the GLP-1 study, cardiac output increased in average
by 0.8  0.1 L min1 (13%) with a maximal increase
(90–120 min after the commencement of the infusion) by
1.1  0.1 L min1 (18%). In the saline study, the peak
increase (90–120 min after the commencement of the
infusion) was 0.3  0.1 L min1 (Fig. 4A and B). Systolic
blood pressure increased significantly by 7  1 mmHg in
the GLP-1 study compared to an increase by
2  1 mmHg in the saline study, (Fig. 5A and B). Dias-
tolic blood pressure remained unchanged in both studies
(Fig. 5C and D). Arterial pulse pressure increased signifi-
cantly in the GLP-1 study by 6  1 compared to an
increase by 3  1 mmHg in the saline study (Fig. 5E and
F). Mean arterial pressure tended to increase by
3  1 mmHg compared with the saline study (Fig. 4C
and D). Heart rate increased significantly in the GLP-1
study by 7  1 bpm, whereas heart rate remained con-
stant in the saline study (Fig. 5G and H).
Effects of GLP-1 on subcutaneous,
abdominal ATBF, leg blood flow, and
splanchnic blood flow
Subcutaneous, abdominal ATBF, leg blood flow, and
splanchnic blood flow during the GLP-1 and saline infu-
sions are shown in Figure 6 and 7.
In the GLP-1 study, subcutaneous abdominal ATBF
began to increase after 40–60 min with a maximal
increase (80–120 min after the commencement of the
infusion) by 2.4 mL min1 100 g tissue1. In the saline
study, the peak increase (80–120 min after the com-
mencement of the infusion) was 1.1 mL min1100 g tis-
sue 1. In the GLP-1 study, leg blood flow increased
significantly to a maximal increase (90–120 min after the
commencement of the infusion) by 195 mL min1 com-
pared to an increase by 83 mL min1 in the saline study.
In both studies, splanchnic blood flow did not change sig-
nificantly, however, in the GLP-1 study, splanchnic blood
flow tended (P = 0.10) to increase initially (0–60 min
after the commencement of the infusion) compared with
the saline study.
Figure 3. Arterial plasma concentrations of insulin (A and B) and arterial blood glucose concentrations (C and D). Left panel shows the time
course of the concentrations during the infusions from 0 to 120 min. Right panel shows the integrated effect during the infusions from 0 to
120 min compared with baseline. Data are presented as means  SE.
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Discussion
In this study, we demonstrate that GLP-1 elicits an
increase in subcutaneous, abdominal ATBF during an
acute administration of GLP-1. Additionally, leg blood
flow increases, whereas splanchnic blood flow remains
unchanged. The increase in adipose tissue and skeletal
muscle blood flow is consistent with most of the GLP-1-
induced increase in cardiac output. Thus, we demonstrate
a significant ~2-fold sustained increase in subcutaneous,
abdominal ATBF, 40–60 min after the commencement of
the GLP-1 infusion, which is a new in vivo observation.
The increase in subcutaneous, abdominal ATBF was
2.4 mL min1 100 g tissue1 during the last 60 min of
the GLP-1 infusion. If we assume that the GLP-1-induced
increase in subcutaneous, abdominal ATBF is representa-
tive for the average body fat mass (14.8 kg, Table 1), it
can be calculated that the increase in ATBF can account
for ~35% of the increase in cardiac output in the last
hour of the experiment.
Previously, only one study has investigated the effect of
GLP-1 on subcutaneous, abdominal ATBF.
Bertin et al. (2001), was not able to demonstrate any
effect of locally infused GLP-1 on subcutaneous, abdomi-
nal ATBF, using the microdialysis technique (ethanol
inflow/outflow ratios). However, this technique is less
sensitive compared with the 133Xe wash-out technique to
detect changes in ATBF (Karpe et al. 2002b). It is well
described (Bulow et al. 1987a; Karpe et al. 2002a), that
ATBF increases postprandially and that hyperinsulinemia
per se cannot account for this increase (Asmar et al.
2010). Recently, we demonstrated in healthy lean subjects
that glucose-dependent insulinotropic polypeptide (GIP)
increases subcutaneous, abdominal ATBF by ~5-fold
(Asmar et al. 2010, 2014, 2016b,c). However, the increase
is dependent on postprandial hyperinsulinemia as well as
hyperglycemia. In contrast to GIP, we demonstrated in
this study, that GLP-1 stimulates subcutaneous, abdomi-
nal ATBF at fasting glucose and insulin concentrations.
Interestingly, the increase in subcutaneous, abdominal
ATBF due to systemic exposure of GLP-1 in this study is
comparable to the 2–3-fold increase in subcutaneous,
abdominal ATBF, usually seen as a response to nutritional
stimuli (Bulow et al. 1987a; Karpe et al. 2002a). Whether
the effect of GLP-1 may be potentiated by hyperglycemia
and hyperinsulinemia, as is the case for GIP, needs to be
studied in additional experiments. The fact, the GLP-10s
vasodilatory effect in adipose tissue is delayed (by 20–
40 min) compared to the GLP-1-induced vasodilation in
skeletal muscle (discussed later) indicates that different
mechanisms could be involved.
Hyperinsulinemia >400 pmol/L has in previous studies
been shown to elicit increase in central sympathetic activ-
ity (Rowe et al. 1981; Vollenweider et al. 1993; Scherrer
Figure 4. Cardiac output (A and B) and mean arterial pressure (C and D). Left panel shows the time course of the measurements during the
infusions from 0 to 120 min. Right panel shows the integrated effect during the infusions from 0 to 120 min compared with baseline. Data are
presented as means  SE.
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and Sartori 1997; Tack et al. 1998; Paolisso et al. 1999).
However, in our previous study, conducted under the
same experimental conditions as applied in this study, we
were not able to measure any significant effect on plasma
levels of noradrenaline or adrenaline. Additionally, heart
rate increased similarly with no effect on heart rate
variability. Altogether, indicating that a significant activa-
tion of the sympathetic nervous system was probably not
induced in this study by the transient decrease in blood
glucose levels induced by GLP-1.
In a study by Hilsted et al. (1985), a decrease in subcu-
taneous ATBF was found during hypoglycemia
Figure 5. Intra-arterial blood pressure (A–F) and heart rate (G and H). Left panel shows the time course of the measurements during the
infusions from 0 to 120 min. Right panel shows the integrated effect during the infusions from 0 to 120 min compared with baseline. Data are
presented as means  SE.
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(~2 mmol/L), induced by insulin injected intravenously.
This vasoconstriction was probably due to stimulation of
vascular a-receptors by increased circulating cate-
cholamines. In this study, blood glucose levels decreased
transiently with a nadir of 4.36  0.12 mmol/L from
time 30–60 min after the commencement of the GLP-1
infusion. In the same time interval (40–60 min), the sub-
cutaneous, abdominal ATBF began to increase. It can be
speculated that the mild hypoglycemia as seen in this
study may have attenuated the initial GLP-1-induced
vasodilation in the adipose tissue.
A sustained increase took place in leg blood flow dur-
ing the GLP-1 infusion. The increase in blood flow in the
examined leg during the GLP-1 infusion was 195 mL/
min. Adipose tissue accounts for ~2.6 kg of the tissue
mass in the examined leg (Table 1). Assuming that leg
adipose tissue and subcutaneous, abdominal ATBF behave
similarly postprandially as demonstrated previously (Man-
olopoulos et al. 2012), ~30% of the leg blood flow
increase can be estimated to have taken place in adipose
tissue. If we assume that the remaining increase in leg
blood flow takes place in the skeletal muscles and that the
skeletal muscles in the leg are representative for whole
body skeletal muscles, this can account for ~40% of the
observed increase in cardiac output (given that ~40% of
total body weight is skeletal muscles).
Figure 6. Subcutaneous, abdominal adipose tissue blood flow (adipose tissue blood flow) (A and B). A shows the time course of the
measurements during the infusions from 0 to 120 min. B shows the integrated effect during the infusions from 0 to 120 min compared with
baseline. Data are presented as means  SE
Figure 7. Leg blood flow (A and B) and splanchnic blood flow (C and D). Left panel shows the time course of the measurements during the
infusions from 0 to 120 min. Right panel shows the integrated effect during the infusions from 0 to 120 min compared with baseline. Data are
presented as means  SE.
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There was a substantial arteriovenous difference in
plasma levels of intact GLP-1 across the lower extremity
and splanchnic vascular bed, possibly reflecting expression
of dipeptidyl peptidase-4 (DPP-4) in the endothelial
membrane of the capillaries in these vascular beds. Inter-
estingly, total GLP-1, and thereby the metabolite GLP-1
9-36amide, which is not a substrate for DPP-4 and if any-
thing acts as an antagonist at the GLP-1 receptor, was
also cleared in the leg. Both intact GLP-1 and its metabo-
lite have previously (Drucker 2016) been reported to
cause vasorelaxation, which was to some extent indepen-
dent of the known GLP-1 receptor. The mechanism
responsible for the increased flow found here cannot be
derived from the present results. Nevertheless, our find-
ings are in accordance with previous studies, demonstrat-
ing an acute GLP-1-induced increase in flow-mediated
dilation of the brachial artery (Nystrom et al. 2004; Basu
et al. 2007). Sjoberg et al. (2014) infused GLP-1
(1.0 pmol kg1 min1) directly into the femoral artery in
healthy subjects leading to supraphysiological plasma
levels of GLP-1 (20-30-fold increase compared with base-
line). Independent of physiological hyperinsulinemia, this
led to microvascular recruitment by ~60% in the vastus
lateralis muscle of the infused leg after 5 min together
with an increase in the diameter of the femoral artery by
~12%. In the noninfused contralateral leg, in which
plasma levels of GLP-1 was within the physiological range
(7–10-fold increase compared with baseline) the effect
was slightly delayed but similar in magnitude. This is in
accord with this study in which skeletal muscle blood
flow (lower limb blood flow corrected for adipose tissue
flow) increased during the GLP-1 infusion, resulting in
similar plasma levels of GLP-1 as seen in the physiological
part of the study by Sjoberg et al. (2014).
The splanchnic blood flow, measured by indocyanine
green clearance technique, remained unaffected during the
GLP-1 infusion apart from a transient tendency to increase
initially after the commencement of the GLP-1 infusion.
We could not demonstrate any significant splanchnic arte-
riovenous difference in plasma concentrations of total
GLP-1 or GLP-1 9-36amide. In a previous study, Trahair
et al. (2014) demonstrated that under postprandial hyper-
glycemia and hyperinsulinemia (induced by a intraduode-
nal glucose infusion; 3 kcal/min) an intravenous infusion
of GLP-1 (0.9 pmol kg1 min1) increased blood flow in
the superior mesenteric artery as measured by ultrasound/
Doppler technique. Flow increased significantly more com-
pared with the saline infusion under postprandial hyper-
glycemia and hyperinsulinemia. However, blood glucose
concentrations were lower during the GLP-infusion.
Whether GLP-1 has a role per se in the vasodilation in the
splanchnic bed cannot be determined from the study by
Trahair et al. (2014) since an oral glucose load initiates a
similar vasodilatory effect (Bulow et al. 1999). An explana-
tion for the constant splanchnic blood flow found in this
study can be, that an increase in the portal vein blood flow
has been counterbalanced by a vasoconstriction in the hep-
atic artery via the intrinsic autoregulation of the hepatic
artery as well as the hepatic arterial buffer response (Eipel
et al. 2010), a mechanism which previously has been
demonstrated with respect to the splanchnic vascular effect
of GIP (Kogire et al. 1988). However, in a recent human
study, it has not been possible to demonstrate a GLP-1-
induced vasodilation in the superior mesenteric artery by
ultrasound/Doppler sonography technique (J.J. Holst,
unpubl. data).
Together with our previous study, we have under simi-
lar conditions altogether examined the vascular biology of
GLP-1 in four major vascular beds; the renal, splanchnic,
adipose tissue, and skeletal muscle. Considering the time
course of blood flow changes in the examined vascular
beds and the changes in cardiac output under slightly
supraphysiological circulating GLP-1 levels, the initial
increase in cardiac output is likely due to an increase in
skeletal muscle blood flow. Since GLP-1 was extracted sig-
nificantly in the lower extremity, this indicates that the
vasodilation in the skeletal muscle may be elicited via
GLP-1 receptors (Pujadas and Drucker 2016). The later
onset increase in ATBF, contributing to the GLP-1-
induced increase in cardiac output may be due to a
derived GLP-1 effect. This mechanism needs to be eluci-
dated in separate experiments.
Limitations of the study
Firstly, the circulating levels of GLP-1 outside the portal
circulation are usually low due to a rapid degradation of
GLP-1 by DPP-4. The slightly supraphysiological levels of
GLP-1 applied in this study may therefore not be com-
pletely translated into normal human physiological condi-
tions. Secondly, the effect of acute elevation of plasma
GLP-1 concentrations for a few hours in a limited num-
ber of patients do not necessarily reflect the chronic ele-
vation of GLP-1 receptor agonist levels in a larger
population with type 2 diabetes treated with a long-acting
GLP-1 receptor agonist. Therefore, the existence of
chronic effects that are not detected in the present experi-
mental setup cannot be excluded.
Conclusions
Under the conditions applied in the present experiments,
acute administration of GLP-1 increases blood flow in
adipose tissue and skeletal muscle, whereas splanchnic
blood flow remains unchanged. Together with an increase
in cardiac work and thereby blood flow, this can explain
2017 | Vol. 5 | Iss. 3 | e13073
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the simultaneous increase in cardiac output in healthy
lean subjects.
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